Use of aldosterone antagonists to inhibit myocardial fibrosis
OwnerKarl T. Weberinventor
Life of this patent
Estimating the term…
Abstract
This invention discloses a method of using an aldosterone antagonist such as spironolactone, at a dosage which does not disrupt a patient's normal electrolyte and water-retention balance, to inhibit myocardial fibrosis, including left ventricular hypertrophy (LVH).
Claims4
A method of inhibiting aldosterone-mediated interstitial fibrosis comprising administering to a patient in need thereof an aldosterone antagonist which suppresses activity at aldosterone receptors in a mammalian body, wherein said aldosterone antagonist is administered in a quantity that is therapeutically effective in suppressing interstitial fibrosis without substantially increasing sodium excretion by the body.
Dependencies are inferred from the claim text.